Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro

Bristol Myers Squibb (BMY) announced that the FDA has approved a label expansion of its lung cancer drug Augtyro (repotrectinib).The regulatory body granted accelerated approval to Augtyro for the treatment of adult and pediatric patients aged 12 years and above with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisf ...